Takeda Pharmaceuticals: Global Homepage

First FDA-approved option for ultra-rare blood clotting disorder

We exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.

Recent News

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

November 27, 2023

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

November 9, 2023

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

November 8, 2023

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

November 7, 2023

View All

Better Health, Brighter Future

Join Us

Work with globally diverse colleagues who are committed to bringing Better Health to people and a Brighter Future to the world.

FIND OUT MORE

Investors

Discover our balanced, diverse portfolio and strategy for sustainable, patient-centered and resilient growth.

FIND OUT MORE

R&D

Fueled by our inherent curiosity, we translate science into highly innovative, life-transforming medicines.

FIND OUT MORE

Our Areas of Focus

Gastrointestinal and Inflammation

Understanding and addressing life-limiting gastrointestinal and inflammatory diseases

Rare Diseases

Working to transform treatments in immunology, hematology, metabolic and lysosomal storage disorders

Plasma-Derived Therapies

Improving the lives of patients with rare and complex chronic diseases through innovation in plasma

Oncology

Aspiring to cure cancer, with inspiration from patients and innovation from everywhere

Neuroscience

Driving medical innovation for patients with neurological diseases

Vaccines

Addressing unmet global health needs through vaccine development against infectious diseases

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Sign up

Takeda Pharmaceuticals: Global Homepage

First FDA-approved option for ultra-rare blood clotting disorder

Recent News

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Better Health, Brighter Future

Join Us

Investors

R&D

Our Areas of Focus

Gastrointestinal and Inflammation

Rare Diseases

Plasma-Derived Therapies

Oncology

Neuroscience

Vaccines

Sign up for investors newsletter